Can a diabetes drug help stop AFib after ablation?
NCT ID NCT03856632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the weight-loss drug liraglutide and a lifestyle program to standard catheter ablation can reduce fat around the heart and improve outcomes for people with atrial fibrillation (AF). About 60 adults with AF and a BMI of 27 or higher will take liraglutide for 3 months before and 6 months after the procedure, along with diet and exercise guidance. The goal is to see if shrinking heart fat can stabilize heart rhythm and reduce the need for repeat procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Liraglutide (a weight-loss drug) plus a lifestyle program (weight management, exercise, and cholesterol control)
What this could lead to
If it works, this could point toward a way to reduce heart fat and make atrial fibrillation less likely to return after a standard ablation procedure.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The drug can cause nausea and other side effects, and the added benefit over ablation alone is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami
Miami, Florida, 33136, United States